SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations  Based on preliminary figures, SCHOTT Pharma expects an increase in sales, EBITDA and EBITDA margin in the second quarter of 2025 (as of March 31, 2025). The company expects Q2 2025 revenues of EUR 252m, corresponding to a year-over-year growth of 10% at constant currenc [ … ]

Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe April 10, 2025, Jagodina, Serbia After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia Production capacity to meet European mar [ … ]

SCHOTT Pharma records good start into fiscal year and confirms full year outlook Q1 2025 revenues reached EUR 230m; decrease of 1% yoy as reported or increase of 4% at constant currencies Q1 2025 EBITDA margin of 25.1% as reported or 26.3% at constant currencies Share of strong-margin high-value solutions (HVS) further increased to 55% Busines [ … ]

SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items SCHOTT Pharma held its Annual General Meeting virtually on February 4, 2025 All items on the agenda were approved by shareholders Dr. Wolfram Carius has been appointed to SCHOTT Pharma’s Supervisory Board, replacing Dr. Wolfgang Wienand   SCHOTT Pharma,  [ … ]